The past year has not been a good one for shareholders in Dechra Pharmaceuticals (LSE: DPH). The share price was down around 30% on a 12-month basis until today, when it shot up following some positive news released after yesterday’s market close.
As I write Friday morning, the shares are about 36% higher than they were at the start of the session.
Possible takeover
That news was about a possible cash offer to take over the firm. That would mean all Dechra shares would be bought by a potential acquirer, subject to agreement.
The possible offer comes from Swedish investment group EQT and the Abu Dhabi Investment Authority. It could be pitched at £40.70 per share. Dechra has said it would recommend such an offer, subject to terms and conditions.
However, the offer is well below the share price of just a couple of years ago, so I expect many Dechra shareholders will not welcome any such bid.
Where now for the share price?
Although the shares jumped this morning, they are trading around 7% lower than the possible offer price. There are a number of possible explanations for this.
The offer has not been formally made and therefore has not been agreed. EQT and its partner could walk away. Dechra may decide a deal cannot be struck on the right terms and so decline to recommend it.
If the takeover does go ahead, I expect the Dechra Pharmaceuticals share price to rise to roughly the offer level. That suggests there could be further upwards moves from the current price.
On top of that, I think there is the possibility another firm may decide to enter the fray now that Dechra is in play. It has a well-established business in an area with resilient demand and strong pricing power. Both financial investors and some of Dechra’s trade rivals are likely running their slide rules over the numbers right now.
I’m not buying
I have long liked the Dechra business and would consider buying its shares. But the reason I have not is because I feel they have been consistently overpriced. After today’s jump, they trade at a price-to-earnings ratio of over 100. That seems far too high to me.
A buyer might be able to strip out costs while adding manufacturing and distribution muscle. That could mean the current valuation could be attractive in a way that is not true for me as a private investor with a purely financial motivation.
But I do not buy shares just on the basis of a possible takeover bid. If I decided to add Dechra to my portfolio today, it would be as a long-term investor looking to buy into a high-quality business.
I think the current Dechra Pharmaceuticals share price remains unattractive. I will therefore not be buying, regardless of what further bid news may emerge.
The post Why is the Dechra Pharmaceuticals share price soaring? appeared first on The Motley Fool UK.
Don’t miss this top growth pick for the ‘cost of living crisis’
While the media raves about Google and Amazon, this lesser-known stock has quietly grown 880% – with a:
Greater than 20X increase in margins
Nearly 60% compounded revenue growth over 5 years – more than Apple, Amazon and Google!
A 3,000% earnings explosion
Of course, past performance is no guarantee of future results. However, we think it’s stronger now than ever before. Amazingly, you may never have heard of this company.
Yet there’s a 1-in-3 chance you’ve used one of its 250 brands. Many are household names with millions of monthly website visitors, and that often help consumers compare items, shop around and save.
Now, as the ‘cost of living crisis’ bites, we believe its influence could soar. And that might bring imminent new gains to investors who’re in position today. So please, don’t leave without your FREE report, ‘One Top Growth Stock from The Motley Fool’.
Claim your FREE copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#FFFFFF’);
})()
More reading
abrdn shares yield 7%. Should investors buy them?
Shell’s share price is rising. Is the stock worth buying today?
Better tech stock buy: MercadoLibre vs AMD
How to turn an ISA into £10k of annual passive income
Why is everyone talking about Glencore stock?
C Ruane has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.